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Type 2 diabetic nephropathy (DN) is the most common cause of end-stage renal disease and is increasingly considered as an
inﬂammatory disease characterized by leukocyte inﬁltration at every stage of renal involvement. Inﬂammation and activation of
the immune system are closely involved in the pathogenesis of diabetes and its microvascular complications. Macrophage has been
well recognized to play an important role in type 2 DN, leukocyte inﬁltration, and participated in process of DN, as was proposed
recently. Th1, Th2, Th17, T reg, and cytotoxic T cells are involved in the development and progression of DN. The purpose of this
review is to assemble current information concerning the role of T cells in the development and progression of type 2 DN. Speciﬁc
emphasisisplacedonthepotentialinteractionandcontributionoftheTcellstorenaldamage.Thetherapeuticstrategiesinvolving
T cells in the treatment of type 2 DN are also reviewed. Improving knowledge of the recognition of T cells as signiﬁcant pathogenic
mediators in DN reinforces the possibility of new potential therapeutic targets translated into future clinical treatments.
1.Introduction
Diabetesmellitus(DM)isacomplexsyndromecharacterized
by absolute or relative insulin deﬁciency leading to hyper-
glycemia and an altered metabolism of glucose, fat, and pro-
tein. These metabolic dysfunctions are pathologically associ-
ated with speciﬁc microvascular diseases and various charac-
teristic long-term complications, including diabetic neuro-
pathy, nephropathy, and retinopathy. Diabetic nephropathy
(DN), aﬀecting more than one third of patients with type 1
DM and up to 25% of all patients with type 2 DM, is an ex-
tremely common complication of DM that profoundly con-
tributes to patient morbidity and mortality [1–4]. Diabetic
nephropathy isaleading causeof chronickidney disease, res-
ulting in end-stage renal disease (ESRD) which has became a
major problem facing human health worldwide [1–4]. Rapi
dly increasing rates of DM with profound consequences of
DNaretheprimaryreasonforthisworldwideincrease.Diab-
etic nephropathy (DN) is characterized as pathological ﬁnd-
ings of hypertrophy of glomerular structures, thickening of
the basement membrane, and accumulation of extracellular
matrix (ECM) components. Multiple mechanisms con-
tribute to the development and outcomes of DN, such as an
interaction between metabolic abnormalities, hemodynamic
changes, genetic predisposition and inﬂammatory milieu,
and oxidative stress, constituting a continuous perpetuation
of injury factors for the initiation and progression of both of
DM and DN [5]. Traditionally, metabolic and hemodynamic
factors are the main causes of renal lesions in patients with
type 2 DM and DN, both considered nonimmune diseases
[6–8]. However, recent studies have shown that chronic in-
ﬂammation is associated with the development and progres-
sion of type 2 DM, implying that immunologic and inﬂam-
matory mechanisms may play a pivotal role in the disease
process[9–11].Furthermore,increasedinﬁltrationofmono-
cytes/macrophages and activated T lymphocytes, as well as
augmented expression of inﬂammatory cytokines in the kid-
neys have also been found in patients with DN [9–11].
Serial research has demonstrated that DN is a metabolic and
hemodynamic disorder, with inﬂammation playing a vital
role in the process [12, 13]. Type 1 DM is an autoimmune
disease, and the role of T cell has been well recognized in the2 Experimental Diabetes Research
disease process. However, the role of T cells in type 2 DM
is still debated. Several animal models are ideal for type 2
DM and DN that are extremely similar to that of humans
and provide the tools necessary to investigate associated
mechanisms [14–16]. The purpose of this review is to as-
semble current information concerning the role of T cells in
the development and progression of type 2 DN, as evidenced
from animal models related to human disease. Speciﬁc em-
phasisisplacedonthepotentialinteractionandcontribution
of the T cells to kidney damage. In addition, we also review
the therapeutic strategies involving T cells in the treatment
of type 2 DN.
2.TCells,MetabolicSyndrome, andType2DM
2.1. Adaptive T Cell Immune Response. The immune system
is composed of innate and adaptive immunity. Innate im-
mune system activation associated with chronic inﬂamma-
tion has been revealed to participate in the pathogenesis of
type 2 diabetes and its complications [11]. It is widely re-
cognized that adaptive immunity CD4+ T cells can be dif-
ferentiated into T-helper 1 (Th1), Th2, Th17, and Treg ac-
cording to their cytokine proﬁles [17, 18]. Th1 cells produce
large quantities of interferon-γ (IFN-γ), induce delayed
hypersensitivity reactions, activate macrophages, and pro-
mote cell-mediated immunity. Th2 cells produce mainly
interleukin-4 (IL-4), induce IgE production, suppress Th1
cellactivation,andcontributetohumoralimmunity[17,18].
Th17, the recently discovered CD4+ eﬀector T cell lineage
distinct from Th1 and Th2, is a third distinct subset of T
helper cells preferentially producing interleukin-17, but not
IFN-γ or IL-4. We now have three types of eﬀector helper T
cells: Th1, Th2, and Th17 which are regulated reciprocally
to maintain a balance in immune-mediated disease [19].
Regulatory T cells control adaptive immune responses by
suppressingTcells,NKcells,NKTcells,Bcells,anddendritic
cells [20]. CD8+ T cells recognize antigen in association with
MHC class I molecules and are predominantly cytotoxic.
Cytotoxic T cells use various mechanisms to kill their targets,
including direct cell-cell signaling via surface molecules and
indirect signaling via cytokines.
2.2. Type 1 versus Type 2 DM. T y p e1d i a b e t e si sa no r g a n -
speciﬁc autoimmune disease characterized by a progressive
cell-mediated destruction of pancreatic beta cells, leading
to an absolute deﬁciency of insulin. Both activation of the
T-cell-mediated immune system leading to insulitis and hu-
moral B cell response producing immunoglobulins against
beta cell autoantigens participate in the pathogenesis of type
1D M[ 21, 22]. Developing a more aggressive T-cell pheno-
type and changing the Th1-to-Th2 balance towards a more
proinﬂammatory milieu (Th1 dominant) may be associated
with the progression towards overt diabetes. Furthermore,
evidence demonstrating the association of the Th17 subset
with pathogenesis of type 1 diabetes is rapidly accumulating
[23–25]. By contrast, type 2 diabetes is a nonautoimmune
form of diabetes characterized by insulin resistance and
relative (rather than absolute) insulin deﬁciency. At present,
however,littleisknownabouttheroleofTcellsintheprocess
of insulin resistance, metabolic syndrome, or type 2 DM
[26].
2.3. T Cells in Insulin Resistance, Metabolic Syndrome, and
Type 2 DM. Adipose tissue inﬂammation is now recognized
as a crucial process leading to the metabolic syndrome,
diabetes and atherosclerotic cardiovascular disease [27–29].
However, how adipose inﬂammation is initiated and main-
tained is still unclear. Macrophage inﬁltration of adipose
tissue has been described in both animal models and human
diseases [27]. Accumulation of other immune cells, such as T
cells, has been observed in obese adipose tissue recently [30–
32]. T lymphocytes are known to interact with macrophages
and regulate the inﬂammatory cascade [33]. Nishimura et
al. performed studies to investigate the functional role of T
lymphocytes in adipose inﬂammation [34]. In mice fed a
high-fat diet, larger numbers of CD8+ eﬀector T cells inﬁl-
trated obese epididymal adipose tissue, whereas the numbers
of CD4+ helper and regulatory T cells were diminished. The
phenomenon of inﬁltration by CD8+ T cells precede macro-
phage accumulation, and once CD8+ T cells were depleted
using speciﬁc antibodies, macrophage inﬁltration, adipose
tissue inﬂammation, and systemic insulin resistance were
ameliorated [34]. Nishimura et al. also found that obese
adipose tissue activates CD8+ T cells, which then promote
the recruitment and activation of macrophages in this tissue
[34]. These ﬁndings, indicating that systemic insulin resis-
tance is ameliorated by CD8 depletion and aggravated by
adoptive transferof CD8+ cells, strongly suggest that CD8+ T
cells play essential roles in the initiation and maintenance of
adipose tissue inﬂammation and systemic insulin resistance
[34].
Accumulation of CD8+ T cells in obese epididymal fat
pads was not accompanied by the presence of greater num-
bers of CD8+ T cells in the systemic circulation, suggesting
that CD8+ T cells are activated by endogenous stimuli loca-
lized in the adipose tissue [34]. Coincubation with CD8+ T
cells plus lean adipose tissue may induce macrophage dif-
ferentiation, suggesting that the interactions among CD8+
T cells, macrophages, and adipose tissue may activate and
propagate a local adipose inﬂammatory cascade [34]. In
contrast to CD8+ T cells, numerous CD4+ T cells and regu-
latory T cells were lower. The predominant T-cell eﬀect on
glucose homeostasis, revealed by conducting CD4+ T-cell
reconstitution studies in lymphocyte-free mice, was the
improvement of glucose tolerance, enhanced insulin sensiti-
vity, and lessening of weight gain [35]. Regulatory T cells and
subsets of CD4+ Th2 cells are known to secrete anti-inﬂa-
mmatory cytokines that can inhibit macrophage recruitment
and activation [36]. Whether the reducing numbers of CD4+
and regulatory T cells augment the inﬂammatory response
during the inﬂammatory cascades in obese adipose tissue re-
quires further study to elucidate the detail mechanisms [34].
2.4. Eﬀects of Hyperglycemia and Type 2 DM on T Cells.
Elements of DM can directly or indirectly activate T cells.Experimental Diabetes Research 3
High-glucose concentrations may induce macrophage pro-
ductionofIL-12,whichcanstimulateCD4cellproductionof
IFN-γ [37]. By contrast, hyperglycemia may activate nuclear
factor kB (NF-kB) through PKC and reactive oxygen species
to rapidly stimulate the expression of cytokines [38, 39].
T lymphocytes from patients with diabetes which have an
activated phenotype and TNF-α-expressing Th1 cells are
prevalently detected [40–42]. The expression of IL-1, TNF-
α, and macrophage migration inhibitory factor (MIF) is
markedly upregulated in the injured kidney [43, 44]. Fur-
thermore, longer disease duration results in increased ad-
vancedglycosylationend(AGE)productsandAGE-modiﬁed
proteins, which could bind to the receptor for AGE on
macrophages and T cells, stimulating synthesis and release of
proinﬂammatory cytokines in DM [45–47]. IFN-γ secretion
by T cells can initiate and induce further inﬂammation and
oxidative stress within renal tissues [47]. Advanced gly-
cosylation end (AGE) induces synthesis of IFN-γ that
further accelerates the inﬂammation by the activation of
m a c r o p h a g e sa n dv a s c u l a rc e l l sw i t hr e n a lt i s s u e s[ 42, 47].
3.LeukocyteRecruitment and
Renal InjuryinDN
Although DN has not been considered an inﬂammatory
disease in the past and although metabolic or hemodynamic
factors are the major causes contributing to DN, recent
studies have suggested that DN is an inﬂammatory process,
and immune cells might be involved in its development
and progression [13, 48]. Diabetic nephropathy (DN) is an
inﬂammatory disease with prominent leucocytes inﬁltratiing
the kidneys. Most research has focused on the contribution
of macrophages because they are the foremost inﬁltrating
immune cells in diabetic kidneys [43, 49]. Inﬂammation in-
duced by macrophages may constitute important mecha-
nisms in the progression of DN [43, 49, 50]. The importance
of macrophages in diabetic renal injury has been clearly
demonstrated;however,littleisknownabouttheroleoflym-
phocytes. The levels of circulating activated lymphocytes
were higher in type 1 diabetic patients with proteinuria than
those in nonproteinuria patients [40, 51]. This suggests that
activated T lymphocytes may also be associated with the de-
velopment of type 1 DN. Whether T cells are associated with
the development of type 2 DN is still unknown.
3.1. Lymphocyte Recruitment in Diabetic Kidney. In patients
with type 1 diabetes, T-cell inﬂux and accumulation in the
juxtaglomerular apparatus are the factors that exacerbate
diabetes and correlate with glomerular ﬁltration surface and
albuminexcretionrate[51].Previousinvestigationshavealso
shown folds increasing in glomerular and interstitial CD4+
and CD8+ T cells, as well as in interstitial FOXP3+ regulatory
T cells in diabetic compared with non-diabetic wild-type
mice [40, 51]. The development of early diabetic renal injury
is associated with signiﬁcant lymphocyte inﬁltration. There
is no doubt that immune cells participate in the renal injury
under the conditions of DN, and their migration into the
kidney is a crucial step in the progression of this disease.
Although the detailed mechanisms of leukocyte migration
intorenaltissuesinDNarenotcompletelyunderstood noris
the functional role of T cells within this compartment, it has
been reported that adhesion molecules and the chemokines
are involved in this recruitment [42, 44, 52].
Recruitment of leukocyte is a key event in the disease
progression of DN. Previous studies have demonstrated that
mice deﬁcient in intercellular adhesion molecule-1 (ICAM-
1) may cause defects in macrophages and leukocytes homing
into renal tissues, resulting in substantial reduction of renal
injury [53]. The CD4+ T cells homing into glomeruli of
diabetic kidney were decreased in ICAM-1-deﬁcient-db/db
mice, as compared with those of db/db mice [53]. Because
naive and eﬀector T cells constitutively express LFA-1, and
ICAM-1 expression is found on renal endothelial, epithelial,
andmesangialcells,itislikelythatthisinteractionwillplaysa
signiﬁcant role during T-cell migration into the kidney [54–
56].Chemotacticcytokinesarealsomajorfactorsthatinduce
the recruitment of inﬂammatory cells into the kidney, sub-
sequently amplifying the immune-mediated damage [57].
Once macrophage is inﬁltrated within the diabetic kidney,
the macrophages and macrophage-derived products can
induce further inﬂammation [43]. Monocyte chemoattrac-
tant protein-1 (MCP-1), an important chemokine regulating
macrophage recruitment, is upregulated in patients with DN
[58].Moreover,constitutiveRANTESexpressiondirectssub-
set-speciﬁc homing of CD4+ T cells in the kidney [59]. The
role of RANTES in directing T lymphocyte homing into the
diabetic kidney is not yet clear.
Compared to Type 2 diabetic patients without DN, sign-
iﬁcantlylowerplasmaconcentrationsofsCTLA-4andhigher
concentrations of sCD28 were noted in Type 2 diabetic pa-
tientswithDN[60].Furthermore,plasmasCD28andsCD80
were found to be positively correlated with the fasting urine
albumin,creatinineratioinDNpatients.Thediseaseseverity
of DN related with elevated soluble adhesion molecule vas-
cularcelladhesionmolecule-1andP-selectinwerealsofound
[60]. Costimulatory molecules, together with leukocyte ad-
hesion molecules, are crucial for T lymphocyte and leuko-
cyte-mediatedinﬂammatoryresponses.Theaberrantexpres-
sion of soluble costimulatory molecules and adhesion mole-
culesmayberelatedtotheactivationofTcellsandleukocytes
in the progression of inﬂammation in type 2 DN [60].
3.2. Leukocytes and Diabetic Nephropathy: Cause or Conseq-
uence? Increased inﬁltration of monocytes/macrophages
a n da c t i v a t e dTl y m p h o c y t e s ,a sw e l la sa u g m e n t e de x p r e s -
sion of inﬂammatory cytokines in the kidneys, have been
foundinpatientswithDN[9–11].Longerdiseasedurationof
DM results in an increase of advanced glycosylation end
(AGE) products and AGE-modiﬁed proteins that may bind
to leukocytes, stimulating the synthesis and release of pro-
inﬂammatory cytokines in DM [45, 46]. By contrast, an
activated renin-angiotensin-aldosterone system (RAAS) and
endothelial dysfunction, well noted in patients with DM,
have also been proven to be a crucial determinants of leuko-
cyte activation and cytokine expression in generating proin-
ﬂammatoryandproliferativeeﬀects[61–63].Thus,itishigh-
ly possible that metabolic or hemodynamic factors in DN4 Experimental Diabetes Research
may trigger the immune-mediated inﬂammatory responses
andcytokineproduction.Furthermore,prominentleukocyte
inﬁltration in models of remnant kidneys or unilateral ureter
obstruction, models considered to be nonimmunologically
mediated, was also illustrated. Hence, the accumulation of
leukocyte in the kidneys of DN can be the results of lesions
from high glucose or glomerular hyperperfusion (secondary
to hyperglycemia or hypertension), rather than the cause of
DN. Therefore, leukocytes may be either the cause or the
consequence of DN.
3.3. Interaction and Mechanisms of T-Cell-Mediated Renal
Damage. The scale of CD4+ and CD8+ T cells accumulated
in thediabetic kidneys wasmuchsmallerthanthat of macro-
phages in rodent models of both Type 1 and Type 2 DN [43,
64], suggesting that T cells may interact with macrophages to
regulate inﬂammation and renal injury. Activated T cells can
cause injury directly through cytotoxic eﬀects and indirectly
by recruiting and activating macrophages. Proinﬂammatory
cytokines secreted by T (CD4+,C D 8 +)c e l l sc o u l da c t i -
vate neighboring macrophages directly or by stimulating
mesangial cell production of colony stimulating factor-1 and
MCP-1 indirectly [65]. Once macrophages have activated,
they can release nitric oxide, reactive oxygen species, IL-1,
TNF-α, complement factors, and metalloproteinases, all of
which promote renal injury [49, 50]. T cells express the
receptor for AGEs and can respond to AGEs [47]. The acti-
vation of CD4+ and CD8+ T cells by AGE can initiate IFN-γ
secretion by T cells [47], which could induce further inﬂam-
mation and oxidative stress within the diabetic kidney. In
addition, CD8+ c e l l sm a yp e r f o r mac y t o l y t i cf u n c t i o ni nt h e
diabetic kidney. All of these cytokines and molecules pro-
mote inﬂammation and induce further expression of macro-
phage colony-stimulating factor and ICAM-1 in renal cells,
further contributing to renal injury [48, 66].
Nevertheless, inﬁltrating macrophages and T lympho-
cytes are the most probable sources of many cytokines med-
iating the renal injury in DN and its progression. The intrin-
sic renal cells (endothelial, mesangial, glomerular, and tubu-
lar epithelial cells) are able to synthesize many pro-inﬂam-
matory cytokines [67, 68]. At high glucose levels, podocytes
are considered the major sources of IL-1α and IL-1β,a n d
they may also produce MCP-1 [69, 70]. Increased secretion
of TGF-β by peripheral blood mononuclear cells has been
reported in patients with DN and seems to be responsible for
ﬁbrogenic and proliferative eﬀects on ﬁbroblasts [71–73].
Furthermore, the TGF-β is also a crucial pleiotropic cytokine
associatedwiththedevelopmentofTregsandTh17cells[19].
Collectively, induction ofproinﬂammatory andproﬁbrogen-
ic molecules inﬂuences renal damage in diabetes.
The aberrant production of inﬂammatory cytokines and
chemokines, as well as diﬀerential activation of MAPK in
diﬀerent leucocytes (T helper (Th) cells and monocytes), are
the underlying immunopathological mechanisms of type 2
DM patients with DN [74]. An increasing body of evi-
dence indicates that immigrated blood leukocytes might
considerably alter the phenotype of endothelial cells and
increase inﬂammation of the vascular bed [75]. Endothelial
dysfunction is associated with most forms of cardiovascular
disease, such as coronary artery diseases, chronic renal
failure, and diabetes [76]. Interaction of renal tissue macro-
phages and T cells produces various reactive oxygen species,
proinﬂammatory cytokines, metalloproteinases, and growth
factors, which modulate the local response and increase
inﬂammation within the diabetic kidney [5, 8, 77, 78].
4.Roles ofTCellsinType2Diabetic
Nephropathy
4.1. Th1 Cells. The circulating lymphocytes traﬃcking
through tissues may interact with tissue AGEs. Exposure of
activated T lymphocytes to AGE may enhance the expression
of interferon gamma (IFN-γ) indicating that the T cell AGE-
receptor system might be linked to lymphokine production
involving in renal damage. Under conditions of excessive
AGE-protein and AGE lipid accumulation (e.g., aging and
diabetes), enhanced production of AGE-induced IFN-γ may
accelerate immune responses that contribute to tissue injury.
It is well recognized that T helper-1 (Th1) response pre-
cedes and accompanies type 1 diabetes [21]; hence, it is pos-
sible that Th1 cells are prevalent in type 1 diabetic kidney.
Elevated levels of ICAM-1 and P-selectin within the dia-
betic kidney, combined with increased levels of IFN-γ and
MIF, were associated with the homing of eﬀector Th1 cells
in glomeruli [79]. However, little is known about the mecha-
nisms of Th1 cell migration in the type 2 DN model during
the development and progression of kidney diseases. Higher
serum IFN-γ levels, a Th1 cytokine, and positive correlations
between plasma IFN-γ, proteinuria, and estimate glomerular
ﬁltration rate (eGFR) were found in type 2 diabetic patients
with overt nephropathy [80]. Plasma IL-2R levels found in
type 2 DM patients with overt DN were higher than those
without overt nephropathy. Furthermore, a signiﬁcantly
positive correlation was determined between plasma IL-2R
and proteinuria [80]. These results indicate that Th1 cellular
immunity in conjunction with Th1 and proinﬂammatory
cytokines may mediate tissue injury in patients with DN
[80].
4.2. Th2 Cells. Th2 cells, producing IL-4 cytokines, can con-
tribute to humoral immunity, suppress Th1 cell activation,
and function as an inhibitory cytokine of autoimmunity and
inﬂammations [17]. No signiﬁcant change of serum IL-4
level in type 2 DN patients, as compared to those without
nephropathy [80]. Speciﬁc polymorphisms within the IL4R
locusandbyspeciﬁcgenotypesattheIL4R,IL4,andIL13loci
were strongly associated with susceptibility to type 1 DM
[81]. Furthermore, an association of interleukin (IL)-4
intron-3 polymorphism with susceptibility to end-stage
renal disease was discovered [82]. However, the role of IL-
4 gene polymorphisms in type 2 diabetic nephropathy still
requires further evaluation.
IL-10, another important Th2 cytokine, exerts predom-
inantly anti-inﬂammatory and immunosuppressive eﬀects
[83]. Low production capacity of IL-10 associated with the
metabolic syndrome and type 2 DM [84]. Some studies have
revealed elevated IL-10 levels in the sera of diabetic patientsExperimental Diabetes Research 5
with nephropathy, and a positive correlation between IL-10
levels and albuminuria has been suggested to participate in
the DN pathogenesis [85–87]. IL-10 promoter variants and
haplotypes (GTA and GTC) have predictive value in deter-
mining the susceptibility to nephropathy in Tunisian T2DM
patients [88, 89].
4.3. Th17 Cells. Th17 is a third distinct subset of T helper
cells and have been found to play vital roles in the pathogen-
esisofseveralautoimmunediseasessuchasmultiplesclerosis
and rheumatoid arthritis [19]. Increasing evidence demon-
strates that the Th17 cell in type 1 DM in murine model and
human type 1 DM [23–25]. Recently, T cell in type 2 DM
patients has been revealed to be skewed toward a proinﬂam-
matory phenotype, requiring monocytes for maintenance
and promoting chronic inﬂammation through elevated IFN-
γ and IL-17 production [90]. However, IL-17A cannot be
concluded to be associated with nephropathic complications
of type 2 DM, due to an increased serum level of IL-17A
found in patients with nonnephropathy [91].
4.4. Treg Cells. The expression rate of CD4+CD25+Foxp3+
Treg cells between the control group and type 2 diabetic pa-
tientsyieldednosigniﬁcantdiﬀerence[92].Intype2diabetic
patients with microalbuminuria and macroalbuminuria, the
expression of CD4+CD25+Foxp3+ Treg cells was signiﬁcantly
lowered, as compared with that of the control group, and
patients with macroalbuminuria showed signiﬁcantly lower
expression of CD4+CD25+Foxp3+ Treg cells than did the
microalbuminuric patients. Signiﬁcant inverse correlations
were noted between the disease course and the expression
of CD4+CD25+Foxp3+ Treg cells between the urinary albu-
min excretion rate (UAER) and the expression of CD4+
CD25+Foxp3+ Treg cells. Whether the CD4+CD25+Foxp3+
regulatory T cells (Treg) play role in type 2 DN still requires
further investigation [92].
4.5. Cytotoxic T Cells. Adipose tissues can activate CD8+T
cells, which then promote the recruitment and activation
of macrophages resulting in the metabolic syndrome, which
can be signiﬁcantly attenuated by a speciﬁc CD8 antibody
[34]. In the diabetic kidneys of NOD mice, accumulation of
CD8+ cells is associated with increased expression of genes
encodingperforinandgranzymeB,aswellaswithcolocaliza-
tion in immunostaining for perforin [93]. This suggests that
CD8+ cells may perform a cytolytic function in the diabetic
kidney. In streptozocin-induced diabetic nephropathy, pre-
vious studies have shown that the diﬀerence in expression
of CD4+ T cells in control and diabetic kidneys is more sig-
niﬁcant at 1 month than at 8 months, whereas expression of
CD8+ T cells is more signiﬁcant at 8 months. It is speculated
that DN is probably initiated and driven by a Th1 process.
The function of CD8+ T cells, however, becomes more signi-
ﬁcant at later stages of the disease when tissue loss is evident
[94].
5 .T ype2D NandT h e rape u ticS trat egie s
Involving T Cells
Due to the pathogenic complexity of DN, protecting diabetic
patients from the development and progression of renal
injury remains a challenge for physicians. The accumulation
of inﬂammatory cells in renal biopsies of diabetic patients
is associated with tissue damage and a progressive decline
in renal function [95]. In animal models, the use of
immunosuppressants, neutralizing antibodies, and genetic
deﬁciencies has shown that reducing leucocyte accumu-
lation and activation in diabetic kidneys suppresses the
development of renal injury [96]. Many previous studies
have used anti-inﬂammatory strategies that also suppress
accumulation of lymphocytes in diabetic kidneys, indicating
that lymphocytes may also contribute to disease progression.
Inﬂammation plays an important role in the pathogenesis of
proteinuria in DN. Inhibiting renal macrophage recruitment
by immunosuppressant therapy, or modulating of MCP1
or ICAM-1 expression in diabetic mice, demonstrate anti-
proteinuric and renoprotective eﬀects [13, 69, 97–99].
The mammalian target of rapamycin (mTOR) is a ser-
ine/threoninekinasethatplaysapivotalroleinmediatingcell
size and mass, proliferation, and survival [100]. High activa-
tion of mTOR within the kidney has been reported to occur
in DN [101, 102]. Systemic administration of rapamycin,
a speciﬁc and potent inhibitor of mTOR, markedly ame-
liorated pathological changes and renal dysfunctions in
db/db mice [102]. Rapamycin markedly inhibited the inﬂux
of inﬂammatory cells, predominantly lymphocytes, and
macrophages, associated with DN [100–104]. This eﬀect is
likely attributable to rapamycin-induced inhibition of the
proliferation and clonal expansion of B and T lymphocytes
[103–105]. Within the kidney, rapamycin also ameliorates
the release of proinﬂammatory cytokines and chemokines,
such as monocyte chemoattractant protein-1, RANTES, IL-
8, and fractalkine, exacerbating the inﬂammatory process in
DN [103–105]. These results indicate that mTOR activation
plays a pivotal role in the development of DN and that rapa-
mycin could be as a strong therapeutic potential agent for
DN.
Depletion of CD8+ T cells using speciﬁc antibodies could
ameliorate macrophage inﬁltration, adipose tissue inﬂam-
mation, and systemic insulin resistance. Whether depleting
CD8+ T cells could be applied in treatment of DN is still
undetermined. Anti-inﬂammatory or immunosuppressive
treatment has been applied to treat DN in animal models
[106–109]; however, therapeutic approaches targeting T cells
are still limited.
6. Conclusion
Beyondtraditionalmetabolicandhemodynamicriskfactors,
type2DNisnowincreasinglyconsideredasaninﬂammatory
disease. The inﬂammatory process is not only due to an in-
nate immune response dominated by macrophage-mediated
eﬀects, but also by the adaptive immune response mediated
by leukocytes. T cells participate in the development of type
2 DN from processes of insulin resistance, metabolic syn-
drome, and type 2 DM into type 2 DN. The recruitment of
leukocyte is a key event in the disease progression of DN.
Diverse immune cells and cytokines exert important roles
in the pathogenic complexity of development and progres-
sion during the DN process. Interaction of renal tissue6 Experimental Diabetes Research
macrophages and T cells produces various reactive oxygen
species, proinﬂammatory cytokines, metalloproteinases, and
growth factors, which modulate the local response and
increase inﬂammation within the diabetic kidney. A better
understanding of the role of T cells in the context of DN will
create several new opportunities for therapeutic intervention
that may beneﬁt patients with DN.
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